Levofloxacin and macrolides in chronic bronchitis exacerbation: Comparative analysis of the treatment efficacy and nonrelapsing periods

Antibiotiki i Khimioterapiya

Volumn 52, Issue 7-8, 2007, Pages 21-31

  Dvoretsky, L I ^a   Dubrovskaya, N V ^a   Grudinina, S A ^a   Filimonova, O Yu ^a   Sidorenko, S V ^a   Yakovlev, S V ^a  

^a I M SECHENOV FIRST MOSCOW STATE MEDICAL UNIVERSITY   (Russian Federation)

Author keywords

Azithromycin; Chronic bronchitis exacerbation; Clarithromycin; Levofloxacin

Indexed keywords

ANTIINFECTIVE AGENT; AZITHROMYCIN; CLARITHROMYCIN; MACROLIDE; OFLOXACIN;

ADULT; AGED; ARTICLE; CHRONIC BRONCHITIS; COMPARATIVE STUDY; FEMALE; HUMAN; MALE; MIDDLE AGED; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; AZITHROMYCIN; BRONCHITIS, CHRONIC; CLARITHROMYCIN; FEMALE; HUMANS; MACROLIDES; MALE; MIDDLE AGED; OFLOXACIN; TREATMENT OUTCOME; YOUNG ADULT;

EID: 48249128818     PISSN: 02352990     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (12)

1. Anthonisen N. R., Manfreda J., Warren C. P. et al. Antibiotic therapy in exacerbations of chronic obstructive pulmonary disease. Ann Intern Med 1987; 106: 196-204.
2. Russian source
3. Amsden G. W. et al. Efficacy and safety of azithromycin vs levofloxacin in the outpatient treatment of acute bacterial exacerbations of chronic bronchitis. Chest 2003; 123: 772-777.
4. Miller K. Azithromycin vs. levofloxacin for acute chronic bronchitis. Am Fam Phys 2003; 15.
5. Charlene Laino. The safety and efficacy of short-course (3-5 day), 750 mg levofloxacin (LVX) for acute bacterial exacerbation of chronic bronchitis (ABECB) [Abstr. D22]. 100th International Conference of the American Thoracic Society. ORLANDO, FL. May 27, 2004. Poster #516.
6. Charlene Laino. Antimicrobial-resistant Streptococcus pneumoniae isolated from patients with acute bacterial exacerbation of chronic bronchitis [Abstr. A47]. 100th International Conference of the American Thoracic Society. ORLANDO, FL. May 26, 2004. Poster #E28.
7. Miravitlles M. Exacerbations of chronic obstructive pulmonary disease: when are bacteria important? Eur Respir J 2002; 20: Suppl 36: 9-19.
8. Sethi S., Evans N., Grant B. J. B., Murphy T. F. New strains of bacteria and exacerbations of chronic obstructive pulmonary disease. New Engl J Med 2002; 347: 465-471.
9. Anthonisen N. R. Bacteria and exacerbations of chronic obstructive pulmonary disease. Ibid; 2002; 347: 526-527.
10. Peifer G., Veyssier P., Zuck P. Efficacy of levofloxacin (LVF) in the treatment of acute exacerbations of chronic bronchitis (AECB) in patients with risk factors. Europ Resp J 2003; 22: Suppl 45: 3558A.
11. Wilson R., Allegra L., Huchon G. et al. Short and long outcomes of moxifloxacin (MXF) compared to standard antibiotic treatment (STD) in acute exacerbations of chronic bronchitis (AECB). The MOSAIC study. Eur Resp J 2003; 22 (Suppl 45): 3559A.
12. Lode H., Eller J., Linnhoff M. Levofloxacin versus clarithromycin in COPD exacerbation: focus on exacerbation-free interval. Eur Resp J 2004; 24: 947-953.